Opus Genetics, Inc. (IRD)
4.23
+0.03
(+0.71%)
USD |
NASDAQ |
Nov 10, 16:00
4.24
+0.01
(+0.24%)
After-Hours: 20:00
Opus Genetics Price to Book Value : 10.54 for Nov. 10, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 10.54 |
| November 09, 2026 | 10.47 |
| November 06, 2026 | 10.42 |
| November 05, 2026 | 9.984 |
| November 04, 2026 | 10.64 |
| November 03, 2026 | 9.797 |
| November 02, 2026 | 9.223 |
| October 30, 2026 | 9.148 |
| October 29, 2026 | 9.099 |
| October 28, 2026 | 9.173 |
| October 27, 2026 | 8.625 |
| October 26, 2026 | 8.276 |
| October 23, 2026 | 8.650 |
| October 22, 2026 | 9.522 |
| October 21, 2026 | 10.26 |
| October 20, 2026 | 9.996 |
| October 19, 2026 | 9.522 |
| October 16, 2026 | 9.572 |
| October 15, 2026 | 10.10 |
| October 14, 2026 | 10.22 |
| October 13, 2026 | 10.57 |
| October 12, 2026 | 11.57 |
| October 09, 2026 | 11.59 |
| October 08, 2026 | 11.12 |
| October 07, 2026 | 10.99 |
| Date | Value |
|---|---|
| October 06, 2026 | 10.92 |
| October 05, 2026 | 10.92 |
| October 02, 2026 | 11.42 |
| October 01, 2026 | 11.24 |
| September 30, 2026 | 12.06 |
| September 29, 2026 | |
| September 28, 2026 | |
| September 25, 2026 | |
| September 24, 2026 | |
| September 23, 2026 | |
| September 22, 2026 | |
| September 21, 2026 | |
| September 18, 2026 | |
| September 17, 2026 | |
| September 16, 2026 | |
| September 15, 2026 | |
| September 14, 2026 | |
| September 11, 2026 | |
| September 10, 2026 | |
| September 09, 2026 | |
| September 08, 2026 | |
| September 04, 2026 | |
| September 03, 2026 | |
| September 02, 2026 | |
| September 01, 2026 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Rezolute, Inc. | 4.524 |
| Faeth Therapeutics, Inc. | 2.073 |
| Nuvectis Pharma, Inc. | 4.274 |
| ACADIA Pharmaceuticals, Inc. | 2.276 |
| Alnylam Pharmaceuticals, Inc. | 5.633 |
Price to Book Value Related Metrics
| PS Ratio | 49.44 |
| Price | 4.23 |
| Earnings Yield | -37.50% |
| Market Cap | 349.60M |